About Kymab ltd
Kymab Ltd: Revolutionizing Drug and Vaccine Development
Kymab Ltd is a UK-based biopharmaceutical company that specializes in developing novel solutions for drug and vaccine development. The company has been working independently and with partners to create high-quality human antibodies for treating challenging diseases using its unique technology.
Located in Cambridge, Kymab has been at the forefront of innovation in the biopharmaceutical industry. The company's mission is to develop new treatments that can improve the lives of patients suffering from various diseases. With a focus on immuno-oncology, inflammation, haematology, and infectious diseases, Kymab is building a rich pipeline of assets that are expected to enter clinical studies in 2017.
Kymab's Unique Technology
Kymab's technology platform is based on its proprietary Kymouse™ transgenic mouse model. This model allows the company to generate fully human monoclonal antibodies with high affinity and specificity against any target antigen. The Kymouse™ model enables rapid antibody discovery by mimicking the human immune system more closely than traditional animal models.
The use of this unique technology has allowed Kymab to develop a diverse range of therapeutic candidates with potential applications across multiple disease areas. By leveraging its expertise in antibody engineering, Kymab can optimize these candidates for improved efficacy and safety profiles.
Therapeutic Areas
Immuno-Oncology: Immuno-oncology is an emerging field that focuses on harnessing the power of the immune system to fight cancer. Kymab's immuno-oncology pipeline includes several promising candidates targeting different checkpoints involved in regulating T-cell activation.
Inflammation: Inflammatory disorders such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease affect millions of people worldwide. Kymab's pipeline includes several monoclonal antibodies targeting key cytokines involved in these conditions.
Haematology: Haematological malignancies such as leukemia and lymphoma are a significant unmet medical need. Kymab's pipeline includes several candidates targeting antigens expressed on malignant cells.
Infectious Diseases: Infectious diseases such as COVID-19, influenza, and HIV continue to pose a significant threat to global health. Kymab is developing monoclonal antibodies that can neutralize viral pathogens and prevent infection.
Partnerships
Kymab has established partnerships with leading pharmaceutical companies such as Novo Nordisk, Sanofi, and Roche. These collaborations have enabled the company to leverage its technology platform for the discovery of novel therapeutics in various disease areas.
In 2016, Kymab entered into a strategic partnership with Intrexon Corporation to develop next-generation CAR-T cell therapies for cancer treatment. This collaboration combines Intrexon's synthetic biology expertise with Kymab's antibody engineering capabilities to create innovative cancer treatments.
Conclusion
Kymab Ltd is an innovative biopharmaceutical company that is revolutionizing drug and vaccine development using its unique technology platform. With a focus on immuno-oncology, inflammation, haematology, and infectious diseases, the company is building a rich pipeline of assets that have the potential to transform patient care.
Through its partnerships with leading pharmaceutical companies and collaborations with academic institutions worldwide, Kymab continues to expand its reach in the biopharmaceutical industry. As clinical studies begin in 2017 for many of their therapeutic candidates across multiple disease areas including immuno-oncology; inflammation; haematology; infectious diseases - it will be exciting times ahead for this Cambridge-based firm!